
A new study published in the February 5 issue of Annals of the Rheumatic Diseases finds that allopurinol and febuxostat are associated with about the same risk of hypersensitivity reactions, as compared to gout patients treated with colchicine. The risk is even higher for women and diabetes patients, the authors wrote.




























